A Hybrid Generic Framework for Heart Problem Diagnosis Based on a Machine Learning Paradigm.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: A two-stage hybrid ML/DL framework was evaluated on named heart-disease datasets and a separate 299-patient heart-failure survival dataset. This is a retrospective clinical prediction result, not evidence of clinical benefit or deployment.
Technology: The paper applies multiple ML/DL classifiers in a two-stage feature-selection and voting framework to clinical heart-disease/survival labels.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- The paper applies multiple ML/DL classifiers in a two-stage feature-selection and voting framework to clinical heart-disease/survival labels.
- Limitation / still unknown
- A two-stage hybrid ML/DL framework was evaluated on named heart-disease datasets and a separate 299-patient heart-failure survival dataset. This is a retrospective clinical prediction result, not evidence of clinical benefit or deployment.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC9921250/unicode · https://europepmc.org/article/MED/36772430 · https://doi.org/10.3390/s23031392
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.